VivoSeq
Other

Immunotherapy

0

Pipeline Programs↗

107

Active Trials↗

22

Companies Involved↗

Immunotherapy is an early-stage landscape with 0 programs across 22 companies. The most active players are Bristol-Myers Squibb, Cytosite Biopharma Inc., Inovio Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

54/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalC

Cytosite Biopharma Inc.

0 programs

PreclinicalInovio Pharmaceuticals logo

Inovio Pharmaceuticals

0 programs

PreclinicalC

Celyad Oncology SA

0 programs

PreclinicalA

Allergy Therapeutics

0 programs

PreclinicalC

Calithera Biosciences, Inc

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

311

clinical trials

Completed141 · 45%
Recruiting57 · 18%
Unknown status33 · 11%
Not yet recruiting24 · 8%
Active, not recruiting23 · 7%
Terminated18 · 6%
Other15 · 5%

Clinical Trials

Trial Activity

311 trials

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer
Recruiting·FFudan University·Phase 2·NCT05555888·34 enrolled
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06300424·32 enrolled
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
Recruiting·—·Phase 2·NCT07311408·40 enrolled
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC
Recruiting·—·Phase 2·NCT06725498·50 enrolled
Nasal Mucus Proteome and Immunotherapy
Recruiting·MMedical University of Graz·N/A·NCT02159404·88 enrolled
Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
Recruiting·RRegina Elena Cancer Institute·Phase 2·NCT06771518·37 enrolled
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
Recruiting·OOncology Center of Biochemical Education And Research·N/A·NCT06717243·111 enrolled
Immunotherapy in Patients With Early dMMR Rectal Cancer
Recruiting·OOdense University Hospital·Phase 2·NCT05732389·39 enrolled
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
Recruiting·PProvidence Health & Services·Phase 1·NCT04470024·56 enrolled
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
Recruiting·GGrandPharma (China) Co., Ltd.·Phase 2·NCT07334483·120 enrolled
Nutrition Impact on Immunotherapy of Cancer
Recruiting·QQingdao Central Hospital·Phase 3·NCT06500234·300 enrolled
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Recruiting·EEmory University·Phase 2·NCT07140679·40 enrolled
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
Recruiting·FFundación GECP·Phase 2·NCT05684276·22 enrolled
A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB
Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 4·NCT05493267·30 enrolled
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Recruiting·—·N/A·NCT06599619·30 enrolled
Page 1 of 21

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)